Global RNAi for Therapeutic Consumption Market 2016 Industry Trend and Forecast 2021

Published: Mar, 2017 | Pages: 128 | Publisher: QYResearch
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

The Global RNAi for Therapeutic Consumption Market 2016 Industry Trend and Forecast 2021 is a professional and in-depth study on the current state of the RNAi for Therapeutic market

The report provides a basic overview of the RNAi for Therapeutic industry including definitions, classifications, applications and industry chain structure.

Development policies and plans are discussed as well as manufacturing processes are also analyzed. 

The report then analyzes the global RNAi for Therapeutic expenses, and the sales segment market is also discussed by product type, applications and region.

The major RNAi for Therapeutic market (including United States, Europe, etc.) is analyzed, data including market size, expenses segment market by product type and applications. Then we forecast the 2016-2025 market size of RNAi for Therapeutic.

The report focuses on global major leading companies providing information such as company profiles, expenses, R&D expenses and contact information.
 
Finally the marketing, feasibility of new investment projects are assessed and overall research conclusions offered.

With 163 tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

 Table of Contents

1 Industry Overview	1
1.1 Definition and Specifications of RNAi for Therapeutic	1
1.1.1 Definition of RNAi for Therapeutic	1
1.1.2 Mechanism and Development History RNAi for Therapeutic	2
1.2 Classification of RNAi for Therapeutic	2
1.2.1 siRNA	3
1.2.2 miRNA	4
1.2.3 shRNA	5
1.3 Applications of RNAi for Therapeutic	7
1.3.1 Cancer	8
1.3.2 Cardiovascular	8
1.3.3 HBV	9
1.4 Industry Chain Structure of RNAi for Therapeutic	10
1.5 Industry Overview and Major Regions Status of RNAi for Therapeutic	10
1.5.1 Industry Overview of RNAi for Therapeutic	10
1.5.2 Global Major Regions Status of RNAi for Therapeutic	12
1.6 Industry Policy Analysis of RNAi for Therapeutic	12
1.7 Industry News Analysis of RNAi for Therapeutic	13

2 Technical Data and Manufacturing Plants Analysis	16
2.1 Expenses and Commercial Expenses Date of Global Key Manufacturers in 2015	16
2.2 Headquarter of Global Key RNAi for Therapeutic Manufacturers in 2015	16
2.3 R&D Status and Technology Type of Global RNAi for Therapeutic Key Manufacturers	17
2.4 Therapeutic Areas Analysis of Global RNAi Technology Key Manufacturers in 2015	18
2.5 Pipeline Analysis of Global RNAi for Therapeutic Key Manufacturers in 2015	19
2.5.1 Alnylam Pharmaceuticals Pipeline Analysis of RNAi for Therapeutic	19
2.5.2 Arbutus Biopharma (Tekmira) Pipeline Analysis of RNAi for Therapeutic	20
2.5.3 Arrowhead Research Pipeline Analysis of RNAi for Therapeutic	21
2.5.4 Dicerna Pharmaceuticals Pipeline Analysis of RNAi for Therapeutic	22
2.5.5 Mirna Therapeutics Pipeline Analysis of RNAi for Therapeutic	23
2.5.6 Quark Pharmaceuticals Pipeline Analysis of RNAi for Therapeutic	24
2.5.7 RXi Pharmaceuticals Pipeline Analysis of RNAi for Therapeutic	25
2.5.8 Silence Therapeutics Pipeline Analysis of RNAi for Therapeutic	26
2.5.9 Benitec Biopharma Pipeline Analysis of RNAi for Therapeutic	27
2.5.10 miRagen Therapeutics Pipeline Analysis of RNAi for Therapeutic	28
2.5.11 Sylentis Pipeline Analysis of RNAi for Therapeutic	29
2.5.12 Gradalis Pipeline Analysis of RNAi for Therapeutic	29
2.5.13 Sirnaomics Pipeline Analysis of RNAi for Therapeutic	30
2.5.14 Silenseed Pipeline Analysis of RNAi for Therapeutic	31

3 Global RNAi for Therapeutic Expenses 2011-2016 Analysis	32
3.1 Global 2011-2016E RNAi for Therapeutic Expenses Analysis	32
3.2 Global 2011-2016E RNAi for Therapeutic Expenses by Companies	32
3.3 Global 2011-2016E RNAi for Therapeutic Expenses by Product Type	34
3.4 Global 2011-2016E RNAi for Therapeutic Expenses by Applications	35
3.5 Global 2011-2016E RNAi for Therapeutic Expenses by Region	37

4 United States RNAi for Therapeutic Expenses Analysis	39
4.1 United States 2011-2016E RNAi for Therapeutic Expenses Analysis	39
4.2 United States 2011-2016E RNAi for Therapeutic Expenses by Companies	39
4.3 United States 2011-2016E RNAi for Therapeutic Expenses by Product Type	40
4.4 United States 2011-2016E RNAi for Therapeutic Expenses by Applications	42

5 Europe RNAi for Therapeutic Expenses Analysis	44
5.1 Europe 2011-2016E RNAi for Therapeutic Expenses Analysis	44
5.2 Europe 2011-2016E RNAi for Therapeutic Expenses by Companies	44
5.3 Europe 2011-2016E RNAi for Therapeutic Expenses by Product Type	45
5.4 Europe 2011-2016E RNAi for Therapeutic Expenses by Applications	47

6 Other Region RNAi for Therapeutic Expenses Analysis	49
6.1 Other Region 2011-2016E RNAi for Therapeutic Expenses Analysis	49
6.2 Other Region 2011-2016E RNAi for Therapeutic Expenses by Companies	49
6.3 Other Region 2011-2016E RNAi for Therapeutic Expenses by Product Type	50
6.4 Other Region 2011-2016E RNAi for Therapeutic Expenses by Applications	52


7 Market Size of RNAi for Therapeutic Forecast by Region, Type and Application 2016-2025	54
7.1 Market Size (M USD) of RNAi for Therapeutic Forecast by Region	54
7.2 Market Size (M USD) of RNAi for Therapeutic Forecast by Type	56
7.3 Market Size (M USD) of RNAi for Therapeutic Forecast by Application	57

8 Global and Major Regions 2016-2021 RNAi for Therapeutic Expenses Forecast	59
8.1 Global 2016-2021 RNAi for Therapeutic Expenses Forecast	59
8.2 United States 2016-2021 RNAi for Therapeutic Expenses Forecast	60
8.3 Europe 2016-2021 RNAi for Therapeutic Expenses Forecast	61
8.4 Other Region 2016-2021 RNAi for Therapeutic Expenses Forecast	62

9 Analysis of RNAi for Therapeutic Industry Key Manufacturers	63
9.1 Alnylam Pharmaceuticals	63
9.1.1 Company Profile	63
9.1.2 Research Information	64
9.1.3 Expenses, R&D Expenses and R&D Share	64
9.2 Arbutus Biopharma (Tekmira)	66
9.2.1 Company Profile	66
9.2.2 Research Information	66
9.2.3 Expenses, R&D Expenses and R&D Share	67
9.3 Arrowhead Research	69
9.3.1 Company Profile	69
9.3.2 Research Information	70
9.3.3 Expenses, R&D Expenses and R&D Share	70
9.4 Dicerna Pharmaceuticals	72
9.4.1 Company Profile	72
9.4.2 Research Information	73
9.4.3 Expenses, R&D Expenses and R&D Share	73
9.5 Mirna Therapeutics	75
9.5.1 Company Profile	75
9.5.2 Research Information	76
9.5.3 Expenses, R&D Expenses and R&D Share	76
9.6 Quark Pharmaceuticals	78
9.6.1 Company Profile	78
9.6.2 Research Information	79
9.6.3 Expenses, R&D Expenses and R&D Share	79
9.7 RXi Pharmaceuticals	81
9.7.1 Company Profile	81
9.7.2 Research Information	82
9.7.3 Expenses, R&D Expenses and R&D Share	83
9.8 Silence Therapeutics	84
9.8.1 Company Profile	84
9.8.2 Research Information	85
9.8.3 Expenses, R&D Expenses and R&D Share	86
9.9 Benitec Biopharma	87
9.9.1 Company Profile	87
9.9.2 Research Information	88
9.9.3 Expenses, R&D Expenses and R&D Share	88
9.10 miRagen Therapeutics	90
9.10.1 Company Profile	90
9.10.2 Research Information	91
9.10.3 Expenses, R&D Expenses and R&D Share	92
9.11 Sylentis	93
9.11.1 Company Profile	93
9.11.2 Research Information	94
9.11.3 Expenses, R&D Expenses and R&D Share	95
9.12 Gradalis	96
9.12.1 Company Profile	96
9.12.2 Research Information	97
9.12.3 Expenses, R&D Expenses and R&D Share	97
9.13 Sirnaomics	99
9.13.1 Company Profile	99
9.13.2 Research Information	100
9.13.3 Expenses, R&D Expenses and R&D Share	100
9.14 Silenseed	102
9.14.1 Company Profile	102
9.14.2 Research Information	103
9.14.3 Expenses, R&D Expenses and R&D Share	103

10 Global RNAi for Therapeutic Expenses Analysis	105
10.1 2011-2016E Global RNAi for Therapeutic Expenses by Countries	105
10.2 2011-2016E Global RNAi for Therapeutic Expenses Market Share	105

11 Manufacturing Process and Collaborations Analysis of RNAi for Therapeutic	108
11.1 Manufacturing Process Analysis of RNAi for Therapeutic	108
11.2 Key Manufacturer's Collaborations of RNAi for Therapeutic	108

12 New Project SWOT Analysis of RNAi for Therapeutic	112

13 Conclusion of the Global RNAi for Therapeutic Consumption Market 2016 Industry Trend and Forecast 2021	113

List of Tables and Figures

Figure Picture of RNAi for Therapeutic	1
Table Classification of RNAi for Therapeutic	2
Figure Global 2015 RNAi for Therapeutic Expenses Market Share by Product Type	3
Figure siRNA Picture	4
Figure miRNA Picture	5
Figure shRNA Picture	6
Table the differences between siRNA and shRNA	6
Table Applications of RNAi for Therapeutic	7
Figure Global 2015 RNAi for Therapeutic Expenses Market Share by Applications	8
Figure Industry Chain Structure of RNAi for Therapeutic	10
Table Global RNAi for Therapeutic Major Manufacturers	11
Figure Global 2015 RNAi for Therapeutic Expenses Market Share by Region	12
Table Industry Policy of RNAi for Therapeutic	12
Table Industry News List of RNAi for Therapeutic	13
Table Expenses (K USD) and Commercial Expenses Date of Global RNAi for Therapeutic Key Manufacturers in 2015	16
Table Headquarter of Global RNAi for Therapeutic Major Manufacturers in 2015	16
Table R&D Status and Technology Type of Global RNAi for Therapeutic Key Manufacturers	17
Table Therapeutic Areas Analysis of Global RNAi Technology Key Manufacturers in 2015	18
Table Therapeutic Areas Analysis of Global RNAi Technology Key Manufacturers in 2015	19
Table Therapeutic Areas Analysis of Global RNAi Technology Key Manufacturers in 2015	20
Table Therapeutic Areas Analysis of Global RNAi Technology Key Manufacturers in 2015	21
Table Therapeutic Areas Analysis of Global RNAi Technology Key Manufacturers in 2015	22
Table Therapeutic Areas Analysis of Global RNAi Technology Key Manufacturers in 2015	23
Table Therapeutic Areas Analysis of Global RNAi Technology Key Manufacturers in 2015	24
Table Therapeutic Areas Analysis of Global RNAi Technology Key Manufacturers in 2015	25
Table Therapeutic Areas Analysis of Global RNAi Technology Key Manufacturers in 2015	26
Table Therapeutic Areas Analysis of Global RNAi Technology Key Manufacturers in 2015	27
Table Therapeutic Areas Analysis of Global RNAi Technology Key Manufacturers in 2015	28
Table Therapeutic Areas Analysis of Global RNAi Technology Key Manufacturers in 2015	29
Table Therapeutic Areas Analysis of Global RNAi Technology Key Manufacturers in 2015	29
Table Therapeutic Areas Analysis of Global RNAi Technology Key Manufacturers in 2015	30
Table Therapeutic Areas Analysis of Global RNAi Technology Key Manufacturers in 2015	31
Figure Global 2011-2016E RNAi for Therapeutic Expenses (K USD) and Growth Rate	32
Table Global 2011-2016E RNAi for Therapeutic Expenses and Total Expenses (K USD)	32
Table Global 2011-2016E RNAi for Therapeutic Expenses Market Share by Companies	33
Table Global 2011-2016E RNAi for Therapeutic Expenses (K USD) by Product Type	34
Figure Global 2011 RNAi for Therapeutic Expenses Market Share by Product Type	34
Figure Global 2015 RNAi for Therapeutic Expenses Market Share by Product Type	35
Table Global 2011-2016E RNAi for Therapeutic Expenses (K USD) by Applications	35
Figure Global 2011 RNAi for Therapeutic Expenses Market Share by Applications	36
Figure Global 2015 RNAi for Therapeutic Expenses Market Share by Applications	36
Table Global 2011-2016E RNAi for Therapeutic Expenses (K USD) by Region	37
Figure Global 2011 RNAi for Therapeutic Expenses Market Share by Region	37
Figure Global 2015 RNAi for Therapeutic Expenses Market Share by Region	38
Figure United States 2011-2016E RNAi for Therapeutic Expenses (K USD) and Growth Rate	39
Table United States 2011-2016E RNAi for Therapeutic Expenses and Total Expenses (K USD)	39
Table United States 2011-2016E RNAi for Therapeutic Expenses Market Share by Companies	40
Table United States 2011-2016E RNAi for Therapeutic Expenses by Product Type	40
Figure United States 2011 RNAi for Therapeutic Expenses Market Share by Product Type	41
Figure United States 2015 RNAi for Therapeutic Expenses Market Share by Product Type	41
Table United States 2011-2016E RNAi for Therapeutic Expenses (K USD) by Applications	42
Figure United States 2011 RNAi for Therapeutic Expenses Market Share by Applications	42
Figure United States 2015 RNAi for Therapeutic Expenses Market Share by Applications	43
Figure Europe 2011-2016E RNAi for Therapeutic Expenses (K USD) and Growth Rate	44
Table Europe 2011-2016E RNAi for Therapeutic Expenses and Total Expenses (K USD)	44
Table Europe 2011-2016E RNAi for Therapeutic Expenses Market Share by Companies	45
Table Europe 2011-2016E RNAi for Therapeutic Expenses by Product Type (K USD)	45
Figure Europe 2011 RNAi for Therapeutic Expenses Market Share by Product Type	46
Figure Europe 2015 RNAi for Therapeutic Expenses Market Share by Product Type	46
Table Europe 2011-2016E RNAi for Therapeutic Expenses by Applications (K USD)	47
Figure Europe 2011 RNAi for Therapeutic Expenses Market Share by Applications	47
Figure Europe 2015 RNAi for Therapeutic Expenses Market Share by Applications	48
Figure Other Region 2011-2016E RNAi for Therapeutic Expenses (K USD) and Growth Rate	49
Table Other Region 2011-2016E RNAi for Therapeutic Expenses and Total Expenses (K USD)	49
Table Other Region 2011-2016E RNAi for Therapeutic Expenses Market Share by Companies	50
Table Other Region 2011-2016E RNAi for Therapeutic Expenses (K USD) by Product Type	50
Figure Other Region 2011 RNAi for Therapeutic Expenses Market Share by Product Type	51
Figure Other Region 2015 RNAi for Therapeutic Expenses Market Share by Product Type	51
Table Other Region 2011-2016E RNAi for Therapeutic Expenses by Applications (K USD)	52
Figure Other Region 2011 RNAi for Therapeutic Expenses Market Share by Applications	52
Figure Other Region 2015 RNAi for Therapeutic Expenses Market Share by Applications	53
Table Market Size (M USD) of RNAi for Therapeutic Forecast by Region	54
Figure Global Market Size (M USD) and Growth Rate of RNAi for Therapeutic	54
Figure United States Market Size (M USD) and Growth Rate of RNAi for Therapeutic	55
Figure Europe Market Size (M USD) and Growth Rate of RNAi for Therapeutic	55
Figure Asia Market Size (M USD) and Growth Rate of RNAi for Therapeutic	56
Table Market Size (M USD) of RNAi for Therapeutic Forecast by Type	56
Figure RNAi for Therapeutic Forecast by Type Market Share by Type in 2025	57
Table Market Size (M USD) of RNAi for Therapeutic Forecast by Application	57
Figure RNAi for Therapeutic Forecast by Type Market Share by Application in 2025	58
Figure Global 2016-2021 RNAi for Therapeutic Expenses (K USD) and Growth Rate Forecast	59
Figure United States 2016-2021 RNAi for Therapeutic Expenses (K USD) and Growth Rate Forecast	60
Figure Europe 2016-2021 RNAi for Therapeutic Expenses (K USD) and Growth Rate Forecast	61
Figure Other Region 2016-2021 RNAi for Therapeutic Expenses (K USD) and Growth Rate Forecast	62
Table Alnylam Pharmaceuticals Company Profile	63
Figure Research Picture of Alnylam Pharmaceuticals	64
Table RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and R&D Share of Alnylam Pharmaceuticals 2011-2016	64
Figure RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and Growth Rate of Alnylam Pharmaceuticals 2011-2016	65
Figure RNAi for Therapeutic Expenses (K USD) and Global Market Share of Alnylam Pharmaceuticals 2011-2016	65
Table Arbutus Biopharma (Tekmira) Company Profile	66
Figure RNAi for Therapeutic Research Information of Arbutus Biopharma (Tekmira)	66
Table RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and R&D Share of Arbutus Biopharma (Tekmira) 2011-2016	67
Figure RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and Growth Rate of Arbutus Biopharma (Tekmira) 2011-2016	68
Figure RNAi for Therapeutic Expenses (K USD) and Global Market Share of Arbutus Biopharma (Tekmira) 2011-2016	68
Table Arrowhead Research Company Profile	69
Figure Helixate FS Research Information of Arrowhead Research	70
Table RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and R&D Share of Arrowhead Research 2011-2016	70
Figure RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and Growth Rate of Arrowhead Research 2011-2016	71
Figure RNAi for Therapeutic Expenses (K USD) and Global Market Share of Arrowhead Research 2011-2016	71
Table Dicerna Pharmaceuticals Company Profile	72
Figure Research Information of Dicerna Pharmaceuticals	73
Table RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and R&D Share of Dicerna Pharmaceuticals 2011-2016	73
Figure RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and Growth Rate of Dicerna Pharmaceuticals 2011-2016	74
Figure RNAi for Therapeutic Expenses (K USD) and Global Market Share of Dicerna Pharmaceuticals 2011-2016	74
Table Mirna Therapeutics Company Profile	75
Figure Research Information of Mirna Therapeutics	76
Table RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and R&D Share of Mirna Therapeutics 2011-2016	76
Figure RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and Growth Rate of Mirna Therapeutics 2011-2016	77
Figure RNAi for Therapeutic Expenses (K USD) and Global Market Share of Mirna Therapeutics 2011-2016	77
Table Quark Pharmaceuticals Company Profile	78
Figure RNAi for Therapeutic Research Information of Quark Pharmaceuticals	79
Table RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and R&D Share of Quark Pharmaceuticals 2011-2016	79
Figure RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and Growth Rate of Quark Pharmaceuticals 2011-2016	80
Figure RNAi for Therapeutic Expenses (K USD) and Global Market Share of Quark Pharmaceuticals 2011-2016	81
Table RXi Pharmaceuticals Company Profile	81
Figure Research Information of RXi Pharmaceuticals	82
Table RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and R&D Share of RXi Pharmaceuticals 2011-2016	83
Figure RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and Growth Rate of RXi Pharmaceuticals 2011-2016	83
Figure RNAi for Therapeutic Expenses (K USD) and Global Market Share of RXi Pharmaceuticals 2011-2016	84
Table Silence Therapeutics Company Profile	84
Figure RNAi for Therapeutic Research Information of Silence Therapeutics	85
Table RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and R&D Share of Silence Therapeutics 2011-2016	86
Figure RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and Growth Rate of Silence Therapeutics 2011-2016	86
Figure RNAi for Therapeutic Expenses (K USD) and Global Market Share of Silence Therapeutics 2011-2016	87
Table Benitec Biopharma Company Profile	87
Figure RNAi for Therapeutic Research Information of Benitec Biopharma	88
Table RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and R&D Share of Benitec Biopharma 2011-2016	88
Figure RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and Growth Rate of Benitec Biopharma 2011-2016	89
Figure RNAi for Therapeutic Expenses (K USD) and Global Market Share of Benitec Biopharma 2011-2016	90
Table miRagen Therapeutics Company Profile	90
Figure RNAi for Therapeutic Research Information of miRagen Therapeutics	91
Table RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and R&D Share of miRagen Therapeutics 2011-2016	92
Figure RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and Growth Rate of miRagen Therapeutics 2011-2016	92
Figure RNAi for Therapeutic Expenses (K USD) and Global Market Share of miRagen Therapeutics 2011-2016	93
Table Sylentis Company Profile	93
Figure RNAi for Therapeutic Research Information of Sylentis	94
Table RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and R&D Share of Sylentis 2011-2016	95
Figure RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and Growth Rate of Sylentis 2011-2016	95
Figure RNAi for Therapeutic Expenses (K USD) and Global Market Share of Sylentis 2011-2016	96
Table Gradalis Company Profile	96
Figure RNAi for Therapeutic Research Information of Gradalis	97
Table RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and R&D Share of Gradalis 2011-2016	97
Figure RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and Growth Rate of Gradalis 2011-2016	98
Figure RNAi for Therapeutic Expenses (K USD) and Global Market Share of Gradalis 2011-2016	98
Table Sirnaomics Company Profile	99
Figure RNAi for Therapeutic Research Information of Sirnaomics	100
Table RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and R&D Share of Sirnaomics 2011-2016	100
Figure RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and Growth Rate of Sirnaomics 2011-2016	101
Figure RNAi for Therapeutic Expenses (K USD) and Global Market Share of Sirnaomics 2011-2016	101
Table Silenseed Company Profile	102
Figure RNAi for Therapeutic Research Information of Silenseed	103
Table RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and R&D Share of Silenseed 2011-2016	103
Figure RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and Growth Rate of Silenseed 2011-2016	104
Figure RNAi for Therapeutic Expenses (K USD) and Global Market Share of Silenseed 2011-2016	104
Table 2011-2016E Global RNAi for Therapeutic Expenses (K USD) by Countries	105
Figure 2011 Global RNAi for Therapeutic Expenses Market Share	105
Figure 2012 Global RNAi for Therapeutic Expenses Market Share	106
Figure 2013 Global RNAi for Therapeutic Expenses Market Share	106
Figure 2014 Global RNAi for Therapeutic Expenses Market Share	107
Figure 2015 Global RNAi for Therapeutic Expenses Market Share	107
Figure Manufacturing Process Analysis of RNAi for Therapeutic	108
Table Key Manufacturer's Collaborations of RNAi for Therapeutic	108
Table New Project SWOT Analysis of RNAi for Therapeutic	112